Related references
Note: Only part of the references are listed.
Article
Medicine, General & Internal
Robert L. Gottlieb et al.
Summary: The study showed that treatment with bamlanivimab and etesevimab was significantly associated with a reduction in SARS-CoV-2 viral load at day 11 in nonhospitalized patients with mild to moderate COVID-19, compared to placebo. However, bamlanivimab monotherapy did not show a significant reduction in viral load. Ongoing clinical trials will focus on assessing the clinical benefits of antispike neutralizing antibodies in COVID-19 patients.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Review
Virology
Maxwell T. Finkelstein et al.
Summary: This review summarizes recent studies focusing on the development of monoclonal antibodies and vaccines against SARS-CoV-2. By studying the structural details of the virus, important information for the treatment and prevention of COVID-19 can be obtained.
Article
Multidisciplinary Sciences
Cheolmin Kim et al.
Summary: A human monoclonal antibody called CT-P59 has been shown to effectively neutralize SARS-CoV-2 and demonstrate significant therapeutic effects in animal models, making it a promising candidate for COVID-19 treatment.
NATURE COMMUNICATIONS
(2021)
Article
Cell Biology
Yunjiao Zhou et al.
Summary: This study found that neutralizing and ADE abilities of human SARS-CoV-2 antibodies are correlated with non-overlapping RBD epitopes they target.
Review
Biotechnology & Applied Microbiology
Brian Kelley et al.
Summary: There are currently few approved monoclonal antibodies for treating infectious diseases, but many products are being developed for a variety of diseases. The maturation of monoclonal antibody technologies has allowed for faster development of neutralizing monoclonal antibodies to address pandemics. Standardized production processes and economies of scale are crucial for ensuring global access and affordability of these products, particularly for low- and middle-income countries or those at risk of pandemics.
BIOTECHNOLOGY PROGRESS
(2021)
Article
Biochemistry & Molecular Biology
Emma S. Winkler et al.
Summary: This study found that neutralizing human monoclonal antibodies in SARS-CoV-2-infected animals require Fc effector functions for optimal protection, reducing inflammation, improving respiratory mechanics, and being associated with diminished immune signaling and tissue repair.
Article
Multidisciplinary Sciences
Pengfei Wang et al.
Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.
Article
Biochemistry & Molecular Biology
Rita E. Chen et al.
Summary: The study analyzed antibody neutralization activity against a panel of authentic isolates and chimeric SARS-CoV-2 variants, showing significantly reduced neutralizing activity against the B.1.351 variant first identified in South Africa. Antibodies targeting the receptor-binding domain and N-terminal domain, monoclonal antibodies, convalescent sera, and mRNA vaccine-induced immune sera exhibited decreased inhibitory activity against viruses with an E484K spike mutation, suggesting a need for updated monoclonal antibodies or vaccine adjustments to prevent loss of protection against emerging variants.
Article
Microbiology
Hejun Liu et al.
Summary: This study presents a cross-neutralizing antibody, CV38-142, which can accommodate antigenic variation in SARS-related viruses, providing valuable information for addressing current and future antigenic drift in SARS-CoV-2 and protecting against zoonotic SARS-related coronaviruses.
CELL HOST & MICROBE
(2021)
Article
Multidisciplinary Sciences
Raoul De Gasparo et al.
Summary: The bispecific IgG1-like molecule CoV-X2 can simultaneously bind two independent sites on the RBD, prevent spike binding to ACE2, neutralize SARS-CoV-2 and its variants, and protect mice from disease in a mouse model of SARS-CoV-2 infection. This demonstrates the feasibility and efficacy of targeting non-overlapping RBD epitopes with IgG-like bispecific antibodies.
Article
Multidisciplinary Sciences
Ge Song et al.
Summary: This study examines the impact of pre-existing immunity to seasonal endemic coronaviruses on antibody responses to SARS-CoV-2, finding weak evidence of pre-existing cross-reactive serum antibodies in pre-pandemic donors, but evidence of pre-existing cross-reactive memory B cells activated during SARS-CoV-2 infection. Monoclonal antibodies show varying degrees of cross-reactivity with betacoronaviruses, and one neutralizing antibody specific to the S2 subunit of the S protein is identified, suggesting that pre-existing immunity to endemic coronaviruses should be considered in evaluating antibody responses to SARS-CoV-2.
NATURE COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Chunyan Wang et al.
Summary: Research has isolated two human monoclonal antibodies from immunized humanized mice that display cross-reactivity against various beta coronaviruses, targeting the stem helix in the spike S2 fusion subunit. These antibodies block MERS-CoV infection in cells and provide protection against lethal MERS-CoV challenge in mice, showcasing their potential for developing broad-spectrum antibodies. Despite exhibiting cross-reactivity, the antibodies only neutralize MERS-CoV due to subtle epitope differences in the spike S2 fusion subunit.
NATURE COMMUNICATIONS
(2021)
Review
Biochemistry & Molecular Biology
Davide Corti et al.
Summary: Monoclonal antibodies have revolutionized the treatment of several human diseases, including cancer, autoimmunity, and infectious diseases. Lessons learned from the COVID-19 pandemic have paved the way for the development of more monoclonal antibody-based therapeutics.
Letter
Biochemistry & Molecular Biology
Jasdeep Singh et al.
Review
Microbiology
William T. Harvey et al.
Summary: The evolution of SARS-CoV-2 has been characterized by the emergence of mutations and variants that impact virus characteristics. Manufacturers are preparing for possible updates to vaccines in response to changes in the virus population, and it is crucial to monitor genetic and antigenic changes alongside experiments to understand the impacts of mutations.
NATURE REVIEWS MICROBIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Alexandra C. Walls et al.
Article
Multidisciplinary Sciences
Chunyan Wang et al.
NATURE COMMUNICATIONS
(2020)
Article
Multidisciplinary Sciences
Dora Pinto et al.
Article
Biotechnology & Applied Microbiology
Brian Kelley
NATURE BIOTECHNOLOGY
(2020)
Article
Immunology
Wafaa B. Alsoussi et al.
JOURNAL OF IMMUNOLOGY
(2020)
Article
Biochemical Research Methods
Matthew I J Raybould et al.
Article
Multidisciplinary Sciences
Christopher O. Barnes et al.
